A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Read more
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia Read more
Phase 1 trial sponsored by Kura Oncology, Inc. under Protocol Number KO-MEN-008 entitled Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia. Attached for your consideration is a high-level overview of the trial. Read more
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That have a Suboptimal Response to Ruxolitinib. Read more
Clinical, Transplant, and Molecular Predictors of Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis Read more
A MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 2 STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB VERSUS VENETOCLAX AND AZACITIDINE ALONE IN NEWLY DIAGNOSED AML PATIENTS WHO ARE NOT CANDIDATES FOR INTENSIVE THERAPY Read more
Real-world comparative effectiveness and safety of FLT3 inhibitors combined with induction chemotherapy in acute myeloid leukemia Read more
STML-401-0423 A Phase II Multicenter Open-Label Trial of Tagraxofusp (TAG) in Combination with Venetoclax and Azacitadine (VEN/AZA) in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia (AML) who are Ineligible for Intensive Chemotherapy Read more
Effect of Adding Venetoclax to Intensive Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Read more
